Ponatinib Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg, 15 mg, 30 mg, 45 mg
Reference Brands: Iclusig (USA)
Category: Oncology Cancer Care
Ponatinib is a third-generation tyrosine kinase inhibitor that targets BCR‑ABL, including the T315I mutation, which is resistant to earlier TKIs. It is used primarily to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia Ponatinib Hydrochloride is available in Tablets and strengths such as 10 mg, 15 mg, 30 mg, 45 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ponatinib Hydrochloride is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Ponatinib Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Ponatinib Hydrochloride is used for the treatment of certain types of blood cancers, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in patients resistant to other therapies.
It is made from ponatinib hydrochloride, a tyrosine kinase inhibitor synthesized to block the activity of the BCR-ABL protein that drives cancer cell growth.
The commonly known trade name is Iclusig.
Iclusig is marketed by Takeda Pharmaceuticals.
The generic name is ponatinib hydrochloride.
The well-known brand name is Iclusig.
Ponatinib Hydrochloride is manufactured in countries including India, the USA, and select EU regions by branded and generic pharmaceutical manufacturers.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
